IDH2 and glioblastoma: This reclassification was based on the absence of IDH mutations and the presence of histopathological features indicative of GBM-IDHwt, such as microvascular proliferation, necrosis, or specific genetic abnormalities, including TERTp mutation, EGFR amplification, or 7p gain and 10q loss.